Duke-led genome sequencing of Burkitt lymphoma reveals unique mutation
In the first broad genetic landscape mapped of a Burkitt lymphoma tumor, scientists at Duke Medicine (home to the Duke Cancer Institute) and their collaborators identified 70 mutations, including several that had not previously been associated with cancer and a new one that was unique to the disease. Findings from the genetic sequencing of Burkitt lymphoma, an aggressive form of lymphoma, could be used to develop new drugs or aim existing therapies at mutations known to be susceptible. The researchers published their findings online Sunday, Nov. 11, 2012, in the journal Nature Genetics.
Among the research institutions NCI funds across the United States, it currently designates 67 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.